BioSpace News Archive

Medtronic Canada ULC, a subsidiary of Medtronic plc — the world’s largest medical technology, services, and solutions company — has been named on the 2021 lists of Top 50 Great Places to Work in Canada and Best Workplaces™ for Women for the second consecutive year after a thorough and independent analysis conducted by Great Place to Work®.

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that it will hold a conference call for investors on Wednesday, April 28, 2021, at 5:00 p.m. Eastern Time.

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that John Paul (J.P.) Gabriel will be joining as Senior Vice President (SVP), Manufacturing and Supply Chain.

Ardelyx, Inc. today announced that its collaboration partner in Japan, Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin), has initiated four Phase 3 clinical studies in Japan evaluating tenapanor for hyperphosphatemia.

Spectrum Solutions , LLC today announced David J. Vigerust, MS., PhD. has been named the company’s new Chief Scientific Officer. Dr. Vigerust has founded, led as CEO, and previously served as chief scientific officer for a number of progressive life science and advanced biotech companies.

Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that since the Company began offering SARS-CoV-2 testing services in June 2020, it has now received more than 350,000 samples for testing.

Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the appointments of Olivia C. Ware and Katrin Rupalla, Ph.D., to its Board of Directors.

On April 7, 2021 Oncology Pharma, Inc. reported that it had been granted an exclusive worldwide license by Regen BioPharma, Inc. to develop and commercialize pancreatic cancer treatments utilizing Regens proprietary intellectual property pertaining to mRNA.

Open-label, non-randomized, controlled study will span one year and evaluate BT-001’s cognitive behavioral therapy approach to change behaviors at root cause of type 2 diabetes Study to evaluate the durability of treatment effect and total cost of care impact of BT-001 in a diverse, real-world clinical setting with topline primary endpoint data expected in 2H 2022

Benchling, the leading life sciences R&D cloud, has raised $200 million in Series E funding led by Sequoia Capital Global Equities and joined by Altimeter Capital, Byers Capital and Elad Gil. Existing investors participated, including Thrive Capital, Benchmark, Menlo Ventures, Alkeon Capital, ICONIQ, Lux Capital, Spark Capital and Lead Edge Capita